Letter to Belgian and European politicians by dr. Hilde De Smet: Information on the RNA corona vaccine by a Belgian medical doctor

Dear politician,

Since you are probably also influenced by the widespread censorship in this corona debate, as most of the medical doctors and citizens, I (a Belgian medical doctor), wish to share some information with you. This censorship has been installed at the request of the WHO to fight the “infodemic” and approved by the European Commission. (1)

I share this information with you because I believe it is important that you, as policymakers, elected by the people and empowered to make decisions for us, study the full picture before creating a law that could potentially have drastic consequences.

Since the beginning of this year, doctors and scientists have been sharing information and asking questions about this covid-19 epidemic and especially about the vaccine, which, if not consistent with the official story, were removed from social media or labeled “fake news” by fact checkers. YouTube recently confirmed that they removed 200,000 videos criticizing the corona vaccine. (2) Probably even more on Facebook. Many accounts have been blocked on Twitter. The main media just tells the official narrative.

Are you not wondering what these hundreds of thousands of people have to say? In order to form an objective picture of the situation and to find out the “truth”, mustn’t you first hear all the different opinions? To solve a world crisis, isn’t it appropriate to have a lot of experts expressing their opinion, instead of allowing just one official narrative?

  1. Therefore, I would urge you to watch the following video about the upcoming covid-19 vaccine by the American MD Carrie Madej. This will take 20 minutes of your time, which might not be too much to ask from you, before you enact laws that will affect the lives of many millions of people. Afterwards you can put this information aside, or you can do something with it.

    Is the following information true? Will these technologies be implemented in the vaccine? I don’t know. There is no transparency nor communication about this. But as you will see in the word document attached most of the vaccine developing companies have connections with the agencies that develop these technologies. It may seem like Science fiction, but if you study the (official) references underneath, all the technology described in this video really exists and will be implemented soon or later. (5)(6)(7)(8)(9)(10)(11)

    What is 100% certain is that most, if not all, of the vaccines currently being developed for covid-19, will be mRNA vaccines, which will directly affect our genetic material. Never before in history have such vaccines been developed or used. We do not know what the long-term consequences will be, but we can assume that the genetic modifications caused by the vaccine will be passed on to our offspring, and to all future generations. In general, it takes 5 to 10 years to develop a vaccine, which must be tested extensively for safety and efficacy (3). This experimental vaccine will be available in less than a year and is planned to be administered to billions of people. The pharmaceutical companies developing these vaccines have already been granted legal immunity in many countries. (4)

    Is it not permissible to ask serious questions about this?

    20 minutes video by Dr. Carrie Madej on the new covid-19 vaccine

https://www.bitchute.com/video/KjFRsu61fdiX/
(thank you for not dropping out during the first 2.5 minutes)

  1. I would also like to add the “hypothesis” that the covid-19 virus is man-made. Below is a video by Luc Montaigner, 2008 Nobel Prize winner in medicine, and Dr. Li-Meng Yan, a Chinese virologist, who has fled now to the United States.

https://www.bitchute.com/video/RSHWZalQfmHZ/

If this is true, the developed vaccine will only be a temporary solution until the next virus is “released”.

  1. Finally, I would like to share a short video of 1 minute 30 sec comparing the death rate in Argentina, a country that has been in lockdown since March, and Sweden, with no lockdown nor mouth mask obligation. The numbers speak for themselves.

Thank you for doing your own investigation, beyond the official narrative, and making up your own mind before voting in favour of a law on mandatory Covid-19 vaccination.

I don’t know if you want to be vaccinated with this vaccine, but I certainly don’t. And I do not wish to administer it to my own children nor to my patients.

Please let me know if I can provide you with more information and references.

Yours sincerely,
Dr. Hilde De Smet, M.D.
Belgium

  1. EurLex, juni 2020 https://eur-lex.europa.eu/legal-content/NL/TXT/PDF/?uri=CELEX:52020JC0008&qid=1533485886151&from=EN
  2. https://www.facebook.com/notes/rt-dutch/youtube-bevestigt-dat-het-alle-videos-verbiedt-waarin-het-offici%C3%ABle-vaccinverhaa/10214200067075952/
  3. https://m.nieuwsblad.be/cnt/dmf20200804_95956456?fbclid=IwAR0IgiA-6sNVQvE8rMC6O5Gq5xhOulbcN1BhdI7Rw-7eq_pRtJDCxde6SQI
  4. https://www.youtube.com/watch?v=oJXXDLGKmPg

RNA- vaccin – article by Bill Gates

  1. https://www.gatesnotes.com/Health/What-you-need-to-know-about-the-COVID-19-vaccine

On Luciferase and DARPA

  1. https://en.wikipedia.org/wiki/Luciferase
  2. https://be.promega.com/applications/virus-detection-assay-coronavirus-detection-covid-19-sars-cov-2/sars-cov-2-viral-research-vaccine-therapeutic-development/
  3. https://www.scientificamerican.com/article/invisible-ink-could-reveal-whether-kids-have-been-vaccinated/
  4. Darpa https://www.defenseone.com/technology/2020/03/military-funded-biosensor-could-be-future-pandemic-detection/163497/
  5. Darpa SBIR: Profusa Implantable Biosensors https://www.youtube.com/watch?v=jzOeY2DVHyE
  6. Direct Neural Interface and DARPA – Dr. Justin Sanches https://www.youtube.com/watch?v=nvUHDK59Igw
  7. https://www.darpa.mil/work-with-us/covid-19

Document attached to the letter – you can click on many words in the text

The original article you find here.

The Frontrunners

AstraZeneca

  • AZD1222; replication-deficient chimpanzee adenovirus vector; developed with Oxford University, and originally called ChAdOx1 nCoV-19; this vector has been used in trials for others vaccines, e.g. RSV vax; uses fetal cells in production; to be sold at cost; agreements with CEPI, GAVI and the Serum Institute of India to manufacture the vax.
  • Funded by BARDA and NIH.
  • About 60% of 1,000 participants in the phase 1/2 trial experienced side effects, and the study was put on hold because someone developed transverse myelitis, which is an inflammation of the spinal cord. It was later said to be an “unrelated neurological illness”.
  • Phase 3 trials were also put on hold due to an adverse event for a UK participant. An informed consent form for this trial stated that effects would probably be mild to moderate, but could be severe, and that “you might experience pain resulting in some difficulty moving your arm, but this should resolve within a few days.” Other concerns were also stated, such as the possibility of enhanced disease and Guillain-Barré syndrome.
  • More trials planned in America and Russia.
  • A trial of ChAdOx1 85A prime with MVA85A boost (for tuberculosis) reported unsolicited adverse events, which included lymphopaenia, neutropaenia leukopaenia, eosinophilia and thrombocytopaenia, as determined by blood tests. One participant got shingles a month after the trial, but this was considered unrelated.
  • Robert F. Kennedy Jr. reported: “Lead developer Andrew Pollard juggles scandalous conflicts that allow him to license, register, and mandate his own untested vaccines to the masses. Pollard is Senior Advisor to Britain’s MRHA Panel which licenses vaccines, chairs Britain’s JVCI committee that mandates them, and advises the European Medicine Agency (EMA). He takes payments from virtually all the big vaccine makers.”
  • Struck a deal with Ethris in 2017 to use their proprietary mRNA technology for respiratory diseases.
  • AstraZeneca may also be using, or planning to use, XNA in some of their products, e.g. modified mRNA and anti-sense oligonucleotides, as well as modified proteins, peptides and recombinant enzymes.
  • Dose capacity 2.94 billion

Novavax

  • NVX-CoV2373; recombinant nanoparticle vax using Matrix M™ adjuvant; $1.6 billion in funding from Operation Warp Speed plus funding from Dept of Defense, HHS and CEPI; doses for US citizens supplied at no costresearch trial with mice for MERS-COV vax in 2014 with funding from the NIH; flu vax called NanoFlu being trialled (the next step is to file for approval!) but gave up on their Ebola glycoprotein vax after phase 1; trials for their RSV vax called ResVax were also unsuccessful.
  • In 2013, Novavax filed a patent application for a vax using an “immunogenic composition comprising a MERS-CoV nanoparticle”.
  • Dose capacity 1.35 billion

Pfizer/BioNTech

Sanofi/GSK (with TranslateBio)

  • Adjuvanted recombinant protein-based vaccine.
  • This technology produces an exact genetic match to proteins found on the surface of the virus, which are then expressed using Sanofi’s insect (baculovirus) expression platform. The technology is used for Sanofi’s licensed recombinant influenza vaccine and a SARS vaccine.
  • Funding of up to $2.1 billion from the U.S. government as part of Operation Warp Speed.
  • Supported by CEPI and Gates Foundation, funded by BARDA; agreement with TranslateBio since 2018 to deliver mRNA vax for up to five infectious diseases; busy building manufacturing facilities; Sanofi Pasteur has four genvax ‘in discovery’, meaning they have not yet begun trials; TranslateBio has four vax that can be inhaled.
  • The baculovirus expression platform is protein engineering in a bioreactor, i.e. producing genetically modified proteins in insect cells.
  • This platform is used to make Cervarix® and Flublok®.

Curevac

  • RNActive platform with mRNA and lipid nanoparticles (LNPs); backed by Gates Foundation; partnered with CEPI; has “an extensive in-house nucleotide sequence library” and has developed a portable RNA printer; product pipeline includes CV7202 rabies vaccine, several others in pre-clinical development including cancer vax and CAS-9 gene editing.
  • Their leading program, for prostate cancer vax CV0104, encoded six antigens, and is detailed in this research paper from 2014. It failed a phase II trial in 2017 and appears to have been discontinued. The only one being trialled now is CV7202 (phase I). Trials for ronavax have not yet begun.

J&J/Janssen

  • Based on its AdVac and PER.C6 platform technologiesfunding from BARDA; manufacturing capacity is being increased;
  • The AdVac platform has been used in a number of clinical trials. According to this WHO document from 2016, vaccines for meningitis, RSV, ebola, prostate cancer, and StaphAureus had reached phase I trial, whilst vaccines for malaria, TB, HCV, HIV, and pandemic flu, had reached phase II trials.

Moderna

  • mRNA1273; Moderna’s mRNA is delivered in lipid nanoparticles, description of its platform also serves to describe mRNA platforms by other companies: “… an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets”
  • funding from ? partnered with Merck and AstraZeneca in ? https://ir.serestherapeutics.com/news-releases/news-release-details/four-boston-biotech-firms-worth-watching
  • delivered the first “clinical-grade batch” of mRNA-1273 just 42 days after sequence selection
  • “Why are we so passionate about messenger RNA?” Moderna President Stephen Hoge asked the attentive audience. “It starts with the question of life,” he explained. “And in fact, all life that we know flows through messenger RNA. … In our language, mRNA is the software of life.”
  • Lots of investment has been raised since it was founded in 2012 and included partnerships with DARPA, AstraZeneca and Merck and funding from the Gates Foundation.
  • Generally perceived to have been operating “in stealth mode” until its plans were revealed at the J.P. Morgan Healthcare Conference in 2017.
  • Moderna was the first company to publish results of a phase I study for the alleged rona, on the 18th of May, 2020. The study was conducted by the NIH.
  • The results announced by the company have received criticism, plus three people experienced systemic symptoms after receiving a second injection of the high dose.
  • Funding for mRNA-1273 from BARDA; manufacturing contracts with Lonza and Catalent.
  • A full round up of Moderna’s product pipeline is in their SEC report, and there are tons of updates here. Their ventures include Onkaido (oncology), Valera (infectious diseases), Elpidera, (rare diseases), and Caperna, (personalized cancer vaccines).
  • Moderna is using Amazon Cloud Services to help deliver personalized cancer vax.
  • The phase III trial of mRNA-1273 is due to be completed in October 2022.
  • Moderna has done a $1.525 billion deal to supply the US government with 100 million doses.
  • The sobering reality that nobody likes to talk about is the legal bit at the end of some of the press releases: “The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the fact that the safety and efficacy of mRNA-1273 has not yet been established; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov”

INOVIO

  • INO-4800; DNA plasmids are injected, then electrical pulses are administered to the injection site. This is called electroporation, and it’s to help the DNA get into the cells – mRNA vaccines only need to enter the cell, while DNA vaccines have to reach the cell nucleus.
  • Funding from the US Dept of Defense to develop the proprietary CELLECTRA 2000 device, used for electroporation; as well as funding from Gates Foundation and CEPI.
  • To develop a new vaccine, Inovio first converts the virus’ RNA into DNA and identifies short sections that will, according to computer simulations, generate the greatest immune response. The plasmids are then produced in large quantities using bacteria”.
  • The first company, partnered with GeneOne, with a MERS vaccine (GLS-5300) to get to phase II in clinical trials; the initial phase I study was conducted in partnership with the Walter Reed Army Institute of Research, and the results presented to the WHO-IVI Joint Symposium for MERS-CoV Vaccine Development in 2018.
  • Development of the MERS vax was supported by a $34 million grant from the Samsung Foundation through the International Vaccine Institute, and $56 million from CEPI.
  • Inovio’s pipeline includes INO-5151 for prostate cancer, INO-1800 for hepatitis B virus, GLS-6150 for hepatitis C virus, INO-4212 for Ebola virus, GLS-5300 for Middle East respiratory syndrome, GLS-5700 for Zika virus infection, PENNVAX-GP for human immunodeficiency virus and INO-4500 for Lassa fever virus.
  • Development of a prophylactic vaccine has been hampered by the lack of MERS-CoV infections, “as well as sourcing suitable small animal models [75, 97, 104]. These factors complicate the definition of a target population for mass prophylactic vaccination and pre-clinical demonstration of vaccine efficacy.”
  • Like the other genvax, INOVIO’s DNA plasmid vax claim to be “off-the-shelf” products, i.e. cold storage is not required, as well as rapid development times, plus they’re relatively cheap to manufacture, and large quantities can be produced.
  • Partners include ApolloBio, Astra Zeneca, DARPA, National Cancer Institute, Regeneron, CEPI, Gates Foundation, and a host of others.
  • INOVIO’s lead candidate is said to be VGX-3100 (for precancerous cervical dysplasia).
  • INOVIO uses HEK-293t cells (this is a fetal cell line).
  • The company are currently faced with lack of manufacturing facilities, but they have some strategic partnerships and plenty of products in the pipeline

(Help ons. Deel dit artikel a.u.b.)